# US 2023/0053463 A1 · Abaloparatide formulations and methods of testing, storing, modifying, and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053463 A1
- Document ID: US20230053463A1
- Status: Published application
- Kind: A1
- Application number: 17/970,811
- Filed: 2022-10-21
- Published: 2023-02-23
- Earliest claimed: 2017-04-28
- Assignees: Radius Health, Inc.
- Applicants: Radius Health, Inc.
- Inventors: Greg Williams; Naveen Palwai; David Hanley
- Web page: https://patentgrep.com/patent/US20230053463A1

## CPC

- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- G01N 30/34: of fluid composition, e.g. gradient (G01N30/36 takes precedence)
- G01N 2030/027: {Liquid chromatography}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.

## Claims

### Claim 1

A method comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10.

### Claim 2 (depends on 1)

The method of claim 1, wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 comprises using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising an aqueous buffer, wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.

### Claim 4 (depends on 3)

The method according to claim 3, wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.

### Claim 5 (depends on 4)

The method according to claim 4, comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 6 (depends on 4)

The method according to claim 4, comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 7 (depends on 4)

The method according to claim 4, comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.

### Claim 9 (depends on 3)

The method according to claim 3, wherein the aqueous buffer comprises ammonium phosphate ((NH4)H2PO4), and the mobile phase further comprises acetonitrile.

### Claim 10 (depends on 3)

The method according to claim 3, wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.

### Claim 11

A method comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising an aqueous buffer, wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.

### Claim 12 (depends on 11)

The method of claim 11, wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.

### Claim 13 (depends on 11)

The method according to claim 11, wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.

### Claim 14 (depends on 13)

The method according to claim 13, comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 15 (depends on 13)

The method according to claim 13, comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 16 (depends on 13)

The method according to claim 13, comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.

### Claim 17 (depends on 11)

The method according to claim 11, wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the aqueous buffer comprises ammonium phosphate ((NH4)H2PO4), and the mobile phase further comprises acetonitrile.

### Claim 19 (depends on 11)

The method according to claim 11, wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.

### Claim 20

An abaloparatide drug product manufacturing process comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10.

### Claim 21 (depends on 20)

The manufacturing process of claim 20, wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.

### Claim 22 (depends on 20)

The manufacturing process of claim 20, wherein analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 comprises using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising an aqueous buffer, wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.

### Claim 23 (depends on 22)

The manufacturing process according to claim 22, wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.

### Claim 24 (depends on 23)

The manufacturing process according to claim 23, comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.

### Claim 25 (depends on 23)

The manufacturing process according to claim 23, comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.

### Claim 26 (depends on 23)

The manufacturing process according to claim 23, comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.

### Claim 27 (depends on 20)

The manufacturing process according to claim 20, wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.

### Claim 28 (depends on 22)

The manufacturing process according to claim 22, wherein the aqueous buffer comprises ammonium phosphate ((NH4)H2PO4), and the mobile phase further comprises acetonitrile.

### Claim 29 (depends on 22)

The manufacturing process according to claim 22, wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.
